|Table of Contents|

The research progress of CAR-T cell therapy in the colorectal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 01
Page:
157-161
Research Field:
Publishing date:

Info

Title:
The research progress of CAR-T cell therapy in the colorectal cancer
Author(s):
Zhang Yan; Qin Baoli
Cancer Hospital of China Medical University，Liaoning Cancer Hospital & Institute，Liaoning Shenyang 110042,China.
Keywords:
CAR-engineered T cells; colorectal cancer; immunotherapy
PACS:
R735.3
DOI:
10.3969/j.issn.1672-4992.2019.01.040
Abstract:
In recent years,the morbidity and mortality of colorectal cancer have shown an increasing trend year by year,which seriously threatens human health.Except for a small proportion of early colorectal cancers can be treated by surgical resection,most still lack effective treatments.As a new mode of immunotherapy，chimeric antigen receptor-engineered T cells(CAR-T) therapy has undoubtedly become one of the most promising treatments.At present,there are many clinical trials targeting colorectal cancer ongoing.This article will focus on CAR-T cells.Here,we will give a brief review on the recent progressabout CAR-T in the treatment of colorectal cancer.

References:

［1］ Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2)：1115-132.
［2］ Davila ML,Riviere I,Wang X,et al.Efficacy and toxicity management of 19-28z CAR-T cell therapy in B cell acute lymphoblastic leukemia［J］.Science Translational Medicine,2014,6(224):224ra225.
［3］ Lee DW.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults:A phase 1 dose-escalation trial［J］.Lancet,2015,85:517-528.
［4］ Batlevi CL,Matsuki E,Brentjens RJ，et al.Novel immunotherapies in lymphoid malignancies［J］.Nat Rev Clin Oncol,2016,13(1):25-40.
［5］Han EQ,Li X,Wang C,et al.Chimeric antigen receptor-engineered T cells for cancer immunotherapy:Progress and challenges［J］.Journal of Hematology & Oncology,2013,6(1):47.
［6］ Patel JM,Dale GA.Cancer CAR tography:Charting out a new approach to cancerimmunotherapy［J］.Immunotherapy,2014,6:675-678.
［7］Yao Chao,Qian Cheng.Opportunities and challenges of CAR-T cells in cancer therapy［J］.Chinese Journal of Cancer Biotherapy，2017,24(1):6-11.［姚超，钱程.CAR-T细胞在肿瘤治疗中的机遇与挑战［J］.中国肿瘤生物治疗杂志，2017,24（1）:6-11.］
［8］Cheadle EJ,Sheard V,Hombach AA,et al.Chimeric antigen receptors for T-cell based therapy［J］.Methods Mol Biol,2012,907:645-666.
［9］Fisher J,Abramowski P,Wisidagamage Don ND,et al.Avoidance of on-target off-tumor activation using a co-stimulation-only chimeric antigen receptor［J］.Molecular Therapy,2017,25(5):1234-1247.
［10］Morgan RA,Yang JC.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2［J］.Mol Ther,2010,18(4):843-851.
［11］Fitzgerald JC,Weiss SL,Maude SL,et al.Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia［J］.Critical Care Medicine,2016,45(2):e124.
［12］ Maude SL,Barrett D.Managing cytokine release syndrome associated with novel T cell-engaging therapies［J］.Cancer J,2014,20（2）：119-122.
［13］Howard SC,Trifilio S,Gregory TK，et al.Tumor lysissyndrome in the era of novel and targeted agents inpatients with hematologic malignancies:A systematicreview［J］.Ann Hematol,2016,95:563-573.
［14］ Li Mengjie,Zou Qiuling,Dang Wei.Chimeric antigen receptor T cell therapy:A new therapeutic strategy for cancer［J］.Shanghai Medical & Pharmaceutical Journal,2017,38(3)：24-27.［李孟捷，邹秋玲，党尉.CAR-T免疫疗法：肿瘤靶向治疗的新策略［J］.上海医药，2017,38(3)：24-27.］
［15］ Pegram HJ,Lee JC.Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning［J］.Blood,2012,119(18):4133-4141.
［16］ Polyak K,Weinberg RA.Transitions between epithelial and mesenchymal states:Acquisition of malignant and stem cell traits［J］.Nat Rev Cancer,2009,9(4):265-273.
［17］Zhang C,Wang Z,Yang Z,et al.Phase I escalating-dosetrial of CAR-T therapy targeting CEA+ metastaticcolorectal cancers［J］.Mol Ther,2017,25（5）:1-11.
［18］Went M,Schoberth A,Ruf P,et al.Immunomonitoring results of a phase Ⅱ/Ⅲ study ofmalignant ascites patients treated with the trifunctional antibody catumaxomab(anti-Ep CAM xanti-CD3)［J］.Cancer Res,2012,72(1):24-32.
［19］Ni Yaping,Chen Yifeng,Zheng Jinyang，et al.The relationship between expression of EpCAMin colorectal cancer with change of DNA ploidy［J］.J Clin Exp Pathol,2018,34(2):132-136.［倪亚平，陈一峰，郑锦阳，等.结直肠癌中EpCAM的表达及与DNA倍体改变的关系［J］.临床与实验病理学杂志,2018,34(2):132-136.］
［20］Jin Z,Maiti S,Huls H,et al.The hyperactive sleeping beauty transposase SB100X improvesthe genetic modifcation of T-cells to express a chimeric antigen receptor［J］.Gene Ther,2011,18(9):849-856.
［21］Wen Ping.The construction of EpCAM-CAR T cell and the killing effect of EpCAM-CAR T cellon colon cancer［D］.Chengdu：Chengdu Medical college,2017.［文萍.靶向EpCAM的嵌合抗原受体修饰的T细胞的构建及其对结肠癌细胞的杀伤研究［D］.成都：成都医学院,2017.］
［22］Blok EJ,Kuppen PJ,Van Leeuwen JE,et al.Cytoplasmic overexpression of HER2:A key factor in colorectal cancer［J］.Clinical Medicine Insights:Oncology,2013，7：41-51.
［23］Chao Li,Liu Daren,Long Yunyue，et al.HER-2 overexpression and survival incolorectal cancer:A Meta-analysis［J］.Biomed & Biotechnol,2014,15(6):582-589.
［24］Richard AM,James CY,Mio K,et al.Case report of a serious adverse event following theadministration of T cells transduced with a chimeric antigen receptor recognizing ERBB2［J］.Molecular Therapy,2010,4(18):843-851.
［25］Kristen M Hege,Emily K Bergsland.Safety,tumor trafficking andimmunogenicity of chimeric antigenreceptor(CAR)-T cells specific for TAG-72 in colorectal cancer［J］.Journal for Immuno Therapy of Cancer,2017,5(1)：22.
［26］Bonifant CL,Jackson HJ,Brentjens RJ,et al.Toxicity and anagement in CAR T-cell therapy［J］.Molecular Therapy Oncolytics,2016,3(C):16011.
［27］Rodgers DT,Mazagova M,Hampton EN,et al.Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies［J］.Proc Natl Acad Sci USA,2016,113(4):E459.
［28］Lanitis E，Poussin M，Klattenhoff AW，et al．Chimericantigen receptor T cellswith dissociated signaling［J］．Cancer Immunol Res，2013,1(1):43-53．
［29］Li J,Li W,Huang K,et al.Chimeric antigen receptor T cell(CAR-T) immunotherapy for solid tumors:Lessons learned and strategies for moving forward［J］.Journal of Hematology & Oncology,2018,11(1):22.
［30］Caruana I,Savoldo B,Hoyos V,et al.Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes［J］.Nat Med,2015,21(5):524-529.
［31］Lim WA，June CH．The principles of engineering immune cells to treat cancer［J］．Cell,2017,168(4):724-740．
［32］Sharma P，Hu-Lieskovan S，Wargo A,et al．Primary，adaptive，and acquired resistance to cancer immunotherapy［J］．Cell，2017，168(4):707-723．
［33］Liu X，Ranganathan R，Jiang S，et al.A chimeric switchreceptor targeting PD1 augments the efficacy of second-generation CAR-T cells in advanced solid tumors［J］．Cancer Res，2016，76(6):1578-1590．
［34］Koneru M,O' Cearbhaill R,Pendharkar S,et al.A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer［J］.Journal of Translational Medicine,2015,13(1):102.
［35］Avanzi MP.IL-18 secreting CAR T cells enhance cell persistence,induce prolonged B cell aplasia and eradicate CD19+ tumor cells withoutneed for prior conditioning［J］.Blood,2016,128(22):8-16.
［36］Boice M,Salloum D,Mourcin F,et al.Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells［J］.Cell,2016,167(2):405-418.
［37］Zhang Ang，Zhang Bin，Chen Hu.The design strategies for improving the efficacy and safety of CAR-T cells［J］.Chin J Cancer Biother，2017,24(5):461-466.［张昂,张斌,陈虎.改进CAR-T细胞有效性和安全性的设计策略［J］.中国肿瘤生物治疗杂志,2017,24(5):461-466.］

Memo

Memo:
-
Last Update: 2018-11-30